Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1174-1179

  Kobelt, G ^a,b   Lindgren, P ^c   Singh, A ^d   Klareskog, L ^b  

^a European Health Economics SAS   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM HEALTH ECONOMICS   (Sweden)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RESOURCE MANAGEMENT; RHEUMATOID ARTHRITIS; SWEDEN;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; IMMUNOGLOBULIN G; MARKOV CHAINS; METHOTREXATE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SICK LEAVE; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23444460855     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.032789     Document Type: Article

References (39)

1. Kobelt G. Health economic assessment of medical technology in chronic progressive diseases: multiple sclerosis and rheumatoid arthritis. Department of Medicine, Division of Health Economics, Stockholm: Karolinska Institute, 2003.
2. Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
3. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis. A Two-country model to estimate costs and consequences RA. Arthritis Rheum 2002;46:2310-19.
4. Fries J, Spitz P, Kraines R, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
5. Torrance G. Measurement of health state utilities for economic appraisal. A review. J Health Econom 1986;5:1-30.
6. Kobelt G, Lindgren P, Young A, Eberhardt K. Cost and effects of leflunomide in the UK. Eur J Health Econom 2002;3:173-9.
7. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-35.
8. Kobelt G, Eberhardt K, Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
9. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: a double-blind randomised controlled trial. Lancet 2004;363:675-81.
10. Sonnenberg F, Beck J. Markov models in medical decision making. Med Decis Making 1993;13:322-38.
11. Scott D, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:122-32.
12. Wolfe F, Mitchell D, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
13. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44:1234-6.
14. Chehata J, Hassell A, Clarke S, Mattey DL, Jones MA, Jones PW, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001;40:447-52.
15. Yelin E, Turpin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7.
16. Mitchell D, Spitz P, Young D, Bloch D, McShane D, Fries J. Survival, prognosis and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:1072-7.
17. Symmons D, Jones M, Scott D, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-7.
18. Wallberg-Jonsson S, Ohlman M, Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.
19. Riise T, Jacobsen B, Gran J, Haga H, Arnesen E. Total mortality is increased in rheumatoid arthritis. A 17 year prospective study. Clin Rheumatol 2001;20:123-7.
20. Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999;58:11-14.
21. Kroot E. No increased mortality in patients with rheumatoid arthritis: up to 10 years follow-up from disease onset. Ann Rheum Dis 2000;59:954-8.
22. DAS website. How to use the DAS, UMC Sint Radbound Nijmegen, 2004. http://www.das-score.nl, accessed 25 February, 2005.
23. Kvien T. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22:1-12.
24. Jacobsson L, Lindroth Y, Marsal L, Tejler L. Malmömodellen för privat och offentlig reumatologisk öppenvard. Läkartidningen 2001;98:4710-16.
25. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
26. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. York: Centre for Health Economics, University of York, 1995.
27. Lindblad S. Svenska RA-registret, www.reumatiker.se/tidningar/nr304/ 040350.pdf, accessed 25 February, 2005.
28. Södra Sjuksvards-Region. Price list, 2004. http://www.srvn.org/ prislista.htm, accessed 25 February, 2005.
29. FASS. Läkemedel i Sverige [Pharmaceutical lexicon]. Stockholm: Läkemedelsinformation AB, 2004, (ISBN 91-85314-71-4.).
30. Statistics Sweden. Statistiska Centralbyran, 2003. www.scb.se/plubikat/ sm/arbetsmarknad.asp, accessed 25 February, 2005.
31. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econom 2000;9:623-30.
32. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econom 2001;10:779-87.
33. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman & Hall, 1998.
34. Bathon J, Genovese M, Martin R, et al. Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA-Trial): observations at 3 years [abstract]. Ann Rheum Dis 2002;61(suppl I):i54.
35. Genovese M, Martin R, Fleischman R, Keystone E, Bathom J, Tsuji W. Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA-Trial): 4 year clinical and radiographic data [abstract]. Ann Rheum Dis 2003;62(suppl I):i183.
36. Almbrand B, Johannesson M, Sjostrand B, Malmberg K, Ryden L. Cost-effectivenesss of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Eur Heart J 2000;21:733-9.
37. Weinblatt ME, Genovese MC, Moreland LW, et al. Efficacy and safety of over 7 years of etanercept therapy in North American patients with early and long-standing rheumatoid arthritis [abstract]. Proceedings of ACR annual meeting 2004.
38. NICE. Betaferon and glatiramer acetate for the treatment of multiple sclerosis. NICE Technology Appraisal Guidance No 32, 2001.
39. Cutler D, Richardson E. The value of health: 1970-90. American Economic Review Papers and Proceedings, 1998; No 88.